Both ALI- and Matrigel-PDOs retained mutations in key CRC-associated genes, including APC and TP53—the two most frequently altered genes in CRC [68]—which drive dysregulation of the WNT pathway and contribute to tumour progression [68,93,94]. This evidence concerns the gene TP53 and colorectal carcinoma.